Manejo de la artritis enteropatica

Abstract

Enteropathic arthritis is an inflammatory rheumatological condition associated with inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. It affects a considerable group of patients, presenting a significant challenge due to its complex diagnosis and multifaceted management. The aim of this study is to describe the management of Enteropathic Arthritis. An exhaustive search of scientific literature was carried out, including case studies, clinical trials, systematic reviews and meta-analyses published between 2019 and 2024. Medical databases such as PubMed, Scopus and Cochrane Library were used to collect relevant information. Pharmacological treatments for AE include sulfasalazine, methotrexate, azathioprine, and TNF inhibitors such as adalimumab and infliximab, which have shown efficacy in reducing inflammation and improving joint symptoms. New biological therapies such as ustekinumab and tofacitinib have shown promising results in patients who do not respond to conventional treatments. Non-pharmacological therapies, such as patient education, exercise, physiotherapy, feeding, use of probiotics and prebiotics, also play an essential role in managing EA, improving quality of life and adherence to treatment. In conclusion, the management of enteropathic arthritis requires a comprehensive approach that combines personalized pharmacological treatments with non-pharmacological therapies. Early identification of the disease and interdisciplinary management are essential to prevent long-term complications and improve the quality of life of patients.